Everest Files IND for China Phase III Trial of Novel Antibiotic
publication date: Jun 12, 2018
Everest Medicines, a US-China startup that in-licenses drugs for China's market, filed an IND to start a Phase III clinical trial of eravacycline in complicated intra-abdominal infections (cIAI). In February, Everest acquired greater China rights to eravacycline in a $43.5 million deal ($7 million upfront) from Tetraphase Pharma of the US. Founded in 2017, Everest began operations with a $50 million investment from C-Bridge Capital, the first tranche of an initial round expected to raise $130 million. More details....
Stock Symbol: (NSDQ: TTPH)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.